DOMH vs. MNPR, TRIB, KPRX, AIH, RDHL, AVTX, PIRS, COEP, MBOT, and NXGL
Should you be buying Dominari stock or one of its competitors? The main competitors of Dominari include Monopar Therapeutics (MNPR), Trinity Biotech (TRIB), Kiora Pharmaceuticals (KPRX), Aesthetic Medical International Holdings Group (AIH), RedHill Biopharma (RDHL), Avalo Therapeutics (AVTX), Pieris Pharmaceuticals (PIRS), Coeptis Therapeutics (COEP), Microbot Medical (MBOT), and NEXGEL (NXGL). These companies are all part of the "medical" sector.
Dominari (NASDAQ:DOMH) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, earnings, profitability, institutional ownership, media sentiment, valuation and risk.
Dominari has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.
In the previous week, Dominari and Dominari both had 1 articles in the media. Dominari's average media sentiment score of 0.00 beat Monopar Therapeutics' score of -0.42 indicating that Dominari is being referred to more favorably in the media.
Monopar Therapeutics has a consensus target price of $2.00, indicating a potential upside of 227.87%. Given Monopar Therapeutics' higher possible upside, analysts clearly believe Monopar Therapeutics is more favorable than Dominari.
42.5% of Dominari shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 9.7% of Dominari shares are held by company insiders. Comparatively, 41.6% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Monopar Therapeutics received 39 more outperform votes than Dominari when rated by MarketBeat users.
Monopar Therapeutics has a net margin of 0.00% compared to Dominari's net margin of -721.11%. Dominari's return on equity of -38.40% beat Monopar Therapeutics' return on equity.
Monopar Therapeutics has lower revenue, but higher earnings than Dominari. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.
Summary
Monopar Therapeutics beats Dominari on 8 of the 14 factors compared between the two stocks.
Get Dominari News Delivered to You Automatically
Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dominari Competitors List
Related Companies and Tools
